Predicting the propofol effect-site concentration that causes deep anesthesia
Prediction of Propofol Effect-Site Concentration Associated With Deep Anesthesia During Induction of General Anesthesia Based on Electroencephalographic Features: a Prospective Observational Study
We will test whether pre‑op EEG patterns, brief cognitive tests, and patient characteristics can predict the propofol level needed to reach deep anesthesia in adults having general anesthesia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 110 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ciusss de L'Est de l'Île de Montréal Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT06346158 on ClinicalTrials.gov |
What this trial studies
This observational, single‑center study records awake high‑density EEG and preoperative cognitive performance in adults scheduled for surgery under general anesthesia, then induces anesthesia with a continuous propofol infusion using target‑controlled methods. Investigators will record the effect‑site concentration (Ce) at which deep anesthesia is observed and analyze interindividual variability. Demographic, cognitive, and EEG features will be related to the Ce for deep anesthesia and used to train and validate machine‑learning models to predict individual sensitivity. The goal is to identify EEG or cognitive signatures that mark increased vulnerability to propofol and to improve individualized dosing strategies.
Who should consider this trial
Good fit: Adults scheduled for any type of surgery under general anesthesia who can communicate in French or English and meet the study's medical inclusion criteria are ideal candidates.
Not a fit: Patients who are excluded by the protocol—such as those with BMI ≥ 35 kg/m2, known propofol contraindications, those requiring rapid sequence induction, anticipated difficult airway/ventilation, or who cannot communicate in French or English—are unlikely to benefit from the study's predictions.
Why it matters
Potential benefit: If successful, this approach could enable more personalized propofol dosing to reduce risks of over‑ or under‑sedation and help identify patients with vulnerable brain phenotypes.
How similar studies have performed: Previous work has shown correlations between age, cognitive status, EEG features, and propofol sensitivity, but comprehensive predictive models combining EEG, cognition, and demographics remain limited and are still being developed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Scheduled for any kind of surgery under general anesthesia. * Adults Exclusion Criteria: * Inability to communicate in French or English, * Known allergy or intolerance or other medical condition that precludes the use of prescribed general anesthesia protocol for this study, * Patients requiring rapid sequence induction, * Anticipated or known difficult intubation patient, * Anticipated or known difficult ventilation patient, * Body mass index ≥ 35 kg.m-2.
Where this trial is running
Montreal, Quebec
- Hopital Maisonneuve-Rosemont — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Louis Morisson, MD, MSc — CIUSSS de l'Est de l'Ile de Montréal
- Study coordinator: Louis Morisson, MD, MSc
- Email: louis.morisson@umontreal.ca
- Phone: 514-252-3400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.